Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral versus parenteral low-dose prednisolone mechanism study
NL-OMON26487Not yet recruiting
- Sponsor
- Amsterdam UMC, location VUmc
- Start
- Dec 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of prednisolone in rheumatoid arthritis (RA), polymyalgia rheumatica (PMR) and psoriatic arthritis (PsA) (2 arms), sponsored by Amsterdam UMC, location VUmc. Primary endpoint: Erythrocyte sedimentation rate. Planned start Dec 2019; status: not yet recruiting.
02
Drugs
prednisolone
03
Conditions
rheumatoid arthritis (RA)polymyalgia rheumatica (PMR)psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NL-OMON26487.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON26487.